IQVIA has launched a SaaS-based clinical data analytics platform, named Clinical Data Analytics Suite (CDAS), for rapid and smart clinical trials.
The new platform merges structured and unstructured trial data to provide a single, standardised setting for easy access and use.
The resulting scalable repository can aid in meeting regulatory requirements for stakeholders to examine operational and clinical data.
In addition, CDAS leverages artificial intelligence and machine learning to deliver quick predictive analytics that will facilitate smart decisions across all trial stages, IQVIA said.
IQVIA Research and Development Technology Solutions chief digital officer Nagaraja Srivatsan said: “The accelerating shift to decentralised trials brings an explosion of data, including opt-in patient level data from connected devices and patient-centric applications.
“Sponsors need an open platform to ingest all trial data, including real world data, and to standardise it into useful models.
“The Clinical Data Analytics Suite supports exploration of information on demand and unlocks previously hidden insights across systems.”
CDAS can convert data analytics from descriptive clinical reports on previous events into predictive insights, which expand trial safety for patients and fast-track drug development.
The platform is designed to automate the delivery of data intelligence to trial workflows.
For stakeholders, this process will allow informed decisions on trial design, site selection and risk, and targeted placement of monitoring resources among others.
The platform can be used with IQVIA’s Orchestrated Clinical Trial solutions and current data archives and systems of the company or third parties.
Furthermore, the company added that clinical data analytic platforms can enhance process transparency, avoid data siloes and aid advanced technologies for new trial methods.
In April last year, IQVIA introduced an open Covid-19 registry platform and technology-powered trial matching solution.